There is a strange disconnect between what we psychiatrists do in daily practice and what official antidepressant treatment guidelines recommend. Treatment guidelines typically say, essentially, that all antidepressants are equal in efficacy, but real psychiatrists have strong personal preferences, based on some combination of the scientific literature, the advice of experts, our clinical experience, and perhaps even the personalities of the last drug reps we saw in the office.
Read More
Everybody knows that chamomile tea is calming, or at least is supposed to be. But it had never been tested in a placebo controlled study, until now. A recent trial compared chamomile capsules to placebo in the treatment of 57 patients with mild to moderate generalized anxiety disorder.
Read More
Dr. Turner and his colleagues published a paper entitled “Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy.” It caused quite a stir in the field. Here, he explains his findings.
Read More
The treatment of adolescent depression has stirred much controversy in recent years. Many have raised doubts about the efficacy of both antidepressants and psychotherapy, and whether medications increase the risk of treatment-emergent suicidality is a divisive issue.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
